New Canine Study From Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution
Presented at Respiratory Drug Delivery 2024, the Nasdepi Canine Study Indicates the Dry Powder Nasal Solution Provides a Faster and...
Pharmaceutical
Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine
BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
Zomedica Expands Global Reach Through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets
Leader Healthcare Group is Chosen as Distribution Partner to Launch Zomedica® Products into the Gulf Cooperation Council Countries in the...
Raphael Pharmaceutical Issues Letter to Shareholders
Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis,...
Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline
Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company’s continued growth....
Organic & Natural Health Association Welcomes New President and Four New Board Members
Todd Norton Named Board President of O&N Health Todd Norton, the vice president of business development at Aker BioMarine, and...
Clene Announces 1-for-20 Reverse Stock Split
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – –...
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH...
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type A FDA Meeting
FDA confirmed resubmission can occur without delayFDA confirmed additional GMP and/or BIMO inspections may occur after resubmissionElevar plans to resubmit...
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Dr. Banerjee previously served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers SquibbBRIDGEWATER, N.J., July...
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a...
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS)...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving...
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in...